AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates
19 Juillet 2023 - 1:30AM
AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and
Organization are Providing False Information Related to
Relationship with Company and its Affiliates
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or
the “Company”) today issued a notice that the Company has learned
that unknown person(s) and/or organization(s) are claiming to
represent AIM ImmunoTech Europe and are using the Company’s name
without authorization. Specifically, there is a LinkedIn profile
promoting misinformation related to AIM’s ongoing clinical
activities, and the profile purports to be linked to the
organization Clavinvest. The unauthorized and unaffiliated profile
uses AIM’s logo and copyrighted imagery to provide the impression
that it has a formal relationship with AIM concerning AIM’s
activities with Erasmus Medical Center in the Netherlands and Prof.
C.H.J. van Eijck. Among other things, the LinkedIn profile promotes
inaccurate information on its relationship with AIM related to the
ongoing clinical efforts in pancreatic cancer, refers the reader to
an entity that could falsely be interpreted to be AIM’s European
subsidiary and implies that this entity will be raising funds.
The Company has no association
whatsoever with the unauthorized third party or any related
profiles associated with Clavinvest. AIM is taking all of
the necessary actions to remove and eliminate this unauthorized
activity.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.For more information,
please visit aimimmuno.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,”
“expect,” “plan,” “anticipate” and similar expressions (as well as
other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
Many of these forward-looking statements involve a number of risks
and uncertainties. Among other things, for those statements, the
company claims the protection of safe harbor for forward-looking
statements contained in the PSLRA. The Company does not undertake
to update any of these forward-looking statements to reflect events
or circumstances that occur after the date hereof.
Aim Immunotech (LSE:0A4Y)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Aim Immunotech (LSE:0A4Y)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024